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Abstract
Background: Clinical care of patients with cyclic Cushing’s syndrome (CS) is challenging. Classical pitfalls include
incorrect subtyping, unnecessary surgical procedures and delayed definite treatment.
Case presentation: A 43-year-old female suffered from a rapidly cycling ectopic CS. She experienced six cycles of
severe hypercortisolism within a 2 year period (maximum plasma cortisol 5316 nmol/L, normal range 124.2–662.4 nmol/L;
maximum urinary free cortisol 79,469 nmol/24 h, normal range < 414 nmol/24 h) lasting 2–9weeks. The episodes were
associated with pronounced hypokalemia (lowest K+ value recorded 2.4 mmol/l) and progressive signs and symptoms of
CS. A bilateral inferior petrosal sinus sampling (BIPSS) performed during a trough phase was false positive for pituitary
ACTH overproduction resulting in unnecessary transsphenoidal surgery while a second BIPSS performed during an active
phase was indicative for ectopic CS. The 18F-DOPA PET/CT showed a pancreatic lesion, which was subsequently partially
removed. Surprisingly, the histopathology was conclusive for ACTH-positive lymph node metastasis located in the retro-
duodenal tissue of an occult neuroendocrine tumor WHO grade II. The primary tumor has not been identified so far and,
because of the persistent hypercortisolism, the patient underwent bilateral adrenalectomy. Two years later, ACTH levels
started to increase progressively. Percutaneous biopsy of a newly identified suspected lesion in the fifth thoracic vertebra
revealed a metastasis with positive staining for ACTH, synaptophysin and chromogranin A. Therapy with carboplatin and
etoposide was started and, since then, the patient underwent 12 cycles of chemotherapy.
Conclusions: We report the challenging case of a rapidly cycling CS secondary to ACTH-secreting neuroendocrine
intestinal tumor of unknown primary. We highlight the importance of performing diagnostic tests only during the phases
of active cortisol secretion and as soon as first symptoms appear to avoid pitfalls.
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Background
Cyclic Cushing’s syndrome (CS) was first described in
the late fifty [1, 2]. It is a rare disorder, in which cortisol
levels are fluctuating, alternating between periods of
hypercortisolism and spontaneous remission. The diag-
nosis of cyclic CS relies on at least three peaks and two
troughs of cortisol production [3]. Case reports from the
literature have shown a great variability in the length of
each period that can ranges from few hours to several
months, sometimes with long disease-free intervals [4–6].
The pathophysiology is not clear, although studies of iso-
lated cases have suggested dopaminergic, serotoninergic
and other hypothalamic influences [7–9]. Biochemical epi-
sodes of cycling occur in 15–36% of cases and they seem
to be very rare in children [10–15]. However, its preva-
lence is likely underestimated, as the diagnosis requires a
careful investigation of cortisol pattern secretion. Patients
with cyclic CS present most frequently with pituitary tu-
mors (54%), followed by ectopic (26%) and adrenocortical
tumors (11%) [14]. The fluctuations of cortisol levels make
the diagnosis of CS extremely challenging and, differenti-
ating between central and ectopic secretion, can incur in
several pitfalls. Here we report the unusual case of a 43-
year-old female with a severe rapidly cycling hypercortiso-
lism secondary to an ectopic occult adrenocorticotropic
hormone (ACTH)-positive neuroendocrine tumor (NET)
and review the relevant literature.
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Case presentation
A 43-year-old female was admitted to a German
Hospital in August 2012 for hypokalemia (lowest K+
value 2.4 mmol/l) muscle weakness, palpitations and
sleeplessness. Patient history and clinical examination
showed arterial hypertension controlled by three antihy-
pertensive drugs and peripheral edema. Hyperaldosteron-
ism was excluded, and oral potassium supplementation
was started. Symptoms resolved spontaneously after 1
month and the patient did not undergo further examina-
tions. In January 2013 the patient was hospitalized for
hypokalemia (lowest K+ value 2.6mmol/l) and uncon-
trolled arterial hypertension despite three antihypertensive
drugs. She complained of weight gain, muscle weakness
and oligomenorrhea. Physical examination revealed mild
hirsutism and oral candidiasis. Renal arterial stenosis and
pheochromocytoma were ruled out. Elevated fasting blood
glucose, elevated ACTH (74 pmol/L with normal values
1.98–11.4 pmol/L) and cortisol levels (1648 nmol/L) were
documented. A suppression test with 2mg dexametha-
sone showed lack of cortisol suppression. Serum cortisol
after 8mg dexamethasone was 513 nmol/L (normal: < 50).
An ACTH-dependent CS was suggested. Two months
later signs and symptoms of hypercortisolism disappeared,
and biochemical remission was documented (Table 1). Pi-
tuitary MRI did not identify a pituitary adenoma, while a
bilateral inferior petrosal sinus sampling (BIPSS) per-
formed in the off-phase was indicative of central ACTH
production because of a strong ACTH increase after cor-
ticotrophin release hormone (CRH) injection (100 μg i.v.)
in the right petrosal sinus and a central to peripheral gra-
dient of 7.3 at 15′ (Fig. 1a). The patient remained without
symptoms for around 5 months. During this time, arterial
blood pressure was medically controlled and potassium
levels were normal without supplementation. In August
2013 a new episode occurred. The worsening of glucose
metabolism required insulin therapy. Basal serum cortisol
and 24 h urinary free cortisol (UFC) levels were highly ab-
normal. A suppression test with 8mg dexamethasone
confirmed lack of cortisol suppression and a new pituitary
MRI identified a suspected pituitary lesion. Only 4 weeks
later Cushing’s symptoms disappeared, and diagnosis of
cyclic CS was established. A 68Ga-DOTATATE PET/CT
was negative. The patient underwent explorative trans-
sphenoidal surgery that showed no pituitary adenoma but
a Crook’s cell hyalinosis in the pituitary gland. In January
2014, after 4 months, hypercortisolism recurred. A sys-
tematic selective venous sampling of all major veins did
not identify an ACTH gradient. A CRH stimulation test
showed no increase in ACTH and cortisol levels, suspi-
cious for ectopic CS. Four weeks later symptoms disap-
peared. An 18-FDG-PET CT was negative and the patient
was referred to our University Hospital. During this
symptom-free interval, midnight salivary cortisol, 24hUFC
and 1mg dexamethasone suppression test remained
slightly abnormal (midnight salivary cortisol 121 nmol/L
(normal range: < 41); 24hUFC 1051 nmol/24 h; serum
cortisol after 1mg dexamethasone 215 nmol/L (normal
range: < 50). In May 2014, the fifth episode occurred last-
ing for 2 weeks (Table 1). CRH levels were low (8.4 pg/
ml), excluding an ectopic CRH secretion. Another BIPSS
was performed and was now in line with ectopic CS
(Fig. 1b). Abdomen MRI and CT, angio MRI and 68Ga-
DOTATATE PET/CT were all negative. An 18F-DOPA
PET/CT identified a lesion close to the pancreatic head,
which was subsequently confirmed by an endoscopic
ultrasound, showing a 13x12mm hypoechoic lesion in the
pancreatic head. Subcutaneous pasireotide was adminis-
tered for 4 days with immediate normalization of cortisol
levels, which remained normal thereafter suggesting a
spontaneous remission rather than a therapeutic effect. In
August 2014, the patient was again symptomatic. Daily
salivary cortisol monitoring documented the rapid and
steep increase in cortisol concentrations, which reached
peak levels in 5 days. The patient was treated with intra-
venous continuous etomidate to control life-threatening
cortisol levels. After discussion in a multidisciplinary
tumor board a Whipple’s intervention with extended
lymphadenectomy was performed. Surprisingly, histopath-
ology did not confirm the pancreatic lesion but identified
several ACTH-positive lymph node metastases. The Ki67
staining was limited due to the strong fragmentation of
the tissue and the presence of numerous intratumoral
lymphocytes. On average, Ki67-positive tumor cell nuclei
were less than 20%. Only in single hot spot region, areas
with up to 25 to 30% positive tumor cell nuclei were iden-
tified. Together with the clinical data (no further primary
suspect focus detectable in the DOPA and DOTATATE
PET/CT and MRI), the findings were suggestive for an
occult, possibly pancreatic, NET WHO grade II with ac-
companying loco-region lymph node metastasis, located
in the retro-duodenal tissue close to the pancreatic head.
The tumor infiltrates reached the broken surface of the
specimen, indicating an incomplete tumor resection. Post-
Table 1 Biochemical data at the time of the first and the
second BIPSS
Values Normal values
Biochemical data at the time of the first BIPSS
ACTH (pmo/L) 14 < 11
Basal cortisol (nmol/L) 566 < 630
UFC nmol/24 h 434 < 789
Biochemical data at the time of the second BIPSS
ACTH (pmo/L) 120 < 11
Basal cortisol (nmol/L) 4858 < 662
UFC nmol/24 h 67,857 < 414
Albani et al. BMC Endocrine Disorders          (2019) 19:105 Page 2 of 6
surgical ACTH levels dropped from 182 to 82 pmol/L and
remained stable between 44 and 66 pmol/L for around
1 month. Because of the incomplete tumor resection,
the patient underwent bilateral adrenalectomy, resolv-
ing symptomatology. The primary tumor remained
occult and, 2 years after adrenalectomy, ACTH levels
started to increase progressively, reaching values of
2676 pmol/L in January 2018. At the same time, chro-
mogranin A raised to 1586 μg/L, compared with
418 μg/L in July 2017. Dopa PET/CT and MRI of the
spine, performed in November 2017 and January 2018
respectively, showed multiple sclerotic lesions suggestive
of bone metastases. A suspected lesion of the fifth thoracic
vertebra underwent percutaneous transpedicular biopsy.
Pathology report documented an ACTH-, synaptophysin-
and chromogranin A-positive metastasis of the NET
tumor with a proliferation rate of 80%. After discussion in
multidisciplinary tumor board, the patient started therapy
with carboplatin and etoposide and, since then, has re-
ceived 12 cycles of chemotherapy. Imaging studies docu-
mented unchanged number and size of target lesions,
reflecting stable disease. Chromogranin A levels dropped
down to 554 μg/l in February 2018, but reached again a
peak of 2657 in June 2018. The last value, in January 2019,
is 1213 μg/L. ACTH levels continued to increase over the
time, reaching in October 2018 values of 11,257 pmol/L.
Discussion and conclusions
Diagnosis and subtyping of cyclic CS are difficult, espe-
cially when periods of hypercortisolism are short and
interspersed by periods of near-normal cortisol levels.
Several pitfalls are possible, and we report here such a
classical scenario in a patient with rapidly cycling
hypercortisolism. The patient experienced, within a 2-
year period, six cycles lasting usually not more than 4
weeks, with pronounced hypokalemia occurring in each
phase (Fig. 2). In such a situation, results of biochemical
testing might be conflicting, and therapeutic decision mak-
ing will often be prolonged. In our patient, identification of
the ACTH source turned out to be extremely challenging.
The BIPSS performed during a phase of normal cortisol se-
cretion raised the suspicion of Cushing’s disease (Fig. 1a)
and lead to unsuccessful pituitary surgery, also because ini-
tial 68Ga-DOTATATE PET/CT imaging did not reveal an
ectopic source. The second BIPSS during an ‘on phase’ of
CS lead to the correct diagnosis, showing a typical ectopic
pattern without any gradient (Fig. 1b). In a similar case,
BIPSS performed during a trough phase was misleading,
wrongly suggesting a peripheral ACTH source [16]. The
confirmation of high basal serum cortisol on the day of per-
forming BIPSS could be helpful to avoid diagnostic failure
and unsuitable testing [17]. Other mistakes in the diagnos-
tic workout of cyclic CS might be due to discrepancies of
test results. For example, cortisol response to dexametha-
sone suppression test can be misleading, reflecting in-
creased or decreased levels of cortisol secretion [3, 18]. The
real prevalence of cyclic CS is hard to establish because of
many difficulties related to the diagnosis. In a review of 65
patients with cyclic CS, pituitary tumors accounted for
54%, followed by ectopic (26%) and adrenocortical tumors
(11%). Considering the low prevalence of patients with CS
secondary to ectopic tumors, an ectopic source of ACTH
Fig. 1 a First BIPSS performed during a trough phase wrongly suggestive of Cushing’s disease. b Second BIPSS performed during a phase of
hypercortisolism suggestive of ectopic ACTH secretion
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hypersecretion seems to be more frequent in patients with
biochemical episode of cycling [14]. Neuroendocrine tu-
mors of the thymus are the most frequently represented,
followed by neuroendocrine bronchial tumors [4, 19–26].
Other tumors reported as responsible of cyclic ectopic CS
are pancreatic, renal and gastric NET [27–29], epithelial
thymoma [30], phaeochromocytoma [31], carotid glomus
tumor [32] and ectopic pituitary adenoma [33]. Surpris-
ingly, although small cell lung carcinoma is frequent in
patients with ectopic CS, biochemical episodes of cycling
seem to be rare. Differentiating between ectopic and central
ACTH source in cyclic CS is extremely challenging and the
localization of the tumor can be very difficult, especially
when it is not visible by imaging, as the fluctuations of
cortisol levels may lead to several pitfalls. In around 13% of
cases, the primary tumor remains unknown [14]. The
68Ga-DOTATATE PET/CT is the first-line PET-imaging
and seems to have more accuracy compared with 18F-
DOPA-PET/CT [34]. However, in our patient 18F-DOPA
PET/CT was suggestive for a pancreatic lesion, which
was not identified by 68Ga-DOTATATE PET/CT.
Another case, in which 18F-DOPA-PET/CT but no
68Ga-DOTATATE PET/CT was able to identify the
tumor lesion, has been reported [35]. In our patient,
the histopathology was unexpected, identifying the
‘pancreatic’ lesion as lymph node metastasis of an occult
NET located in the retro-duodenal tissue adjacent to the
pancreatic head. Because of the incomplete tumor resec-
tion, the patient underwent bilateral adrenalectomy, resolv-
ing the symptomatology. Bilateral adrenalectomy is a safe
and effective treatment when the primary source of ACTH
secretion is not surgically removable [36]. An Italian multi-
centre study conducted in patients with ectopic CS showed
a better survival rate in those who underwent adrenalec-
tomy, in the first 2 years after surgery [37]. Several factors
may affect the prognosis in ectopic CS, such as severity of
hypercortisolism with relative comorbidities, presence of
hypokalaemia, type and grade of the NET and presence of
metastases [37]. Avoiding all the potential pitfalls is of pri-
mary importance in order to speed-up the diagnosis and
prevent unnecessary treatments. In summary, we reported
here the challenging case of a patient with a rapidly cycling
Cushing’s syndrome secondary to ACTH-secreting neuro-
endocrine intestinal tumor of unknown primary, in whom
a BIPSS performed during a trough phase was wrongly
suggestive of central ACTH overproduction. This case
highlights the potential pitfalls occurring in diagnosis, sub-
typing and localization of a tumor, which is cyclically the
source of ACTH hypersecretion. It also demonstrates the
importance of performing diagnostic tests only during the
phases of active cortisol secretion, as soon as first
symptoms appear. In addition, our case is peculiar be-
cause of the histopathology of the suspected pancre-
atic lesion, surprisingly conclusive for lymphonode
metastasis of an occult NET located in the retro-
duodenal tissue. To our knowledge, no similar cases
have been reported in the literature.
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Fig. 2 Potassium levels over the time (weeks). Oral potassium supplementation was regularly started after diagnosis of hypokalemia
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